American Scientific Resources, Incorporated
ASFX
Other OTC0.00
USD
- -
- -
ISIN
US0294413002
CUSIP
029441300
Return %
Stock
S&P500
1Y
-70.00
17.85
3Y
50.00
64.56
5Y
-90.00
69.89
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Neil A. Akshay
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- 1112 Weston Road Weston FL United States of America 33326
- IPO Date
- Sep 11, 1997
- Similar Companies
- Business
- American Scientific Resources, Incorporated (ASFX) develops, manufactures, and markets innovative medical and scientific products for healthcare, laboratory, and research applications. The company offers a diverse portfolio of core products and services, including proprietary diagnostic kits for rapid pathogen detection; high-precision laboratory instruments such as spectrophotometers and centrifuges; sterile consumables like pipettes, gloves, and culture media; and specialized software platforms for data analysis and compliance reporting in regulated environments. These offerings serve clinical laboratories, pharmaceutical companies, academic institutions, and government agencies across North America, Europe, and Asia. Founded in 1987 and headquartered in Irvine, California, ASFX operates primarily in the life sciences and diagnostics segments, with manufacturing facilities in the United States and distribution networks spanning over 20 countries. The company targets B2B customers in biotechnology, diagnostics, and research sectors, emphasizing FDA-compliant solutions and custom OEM services. In the past two years, ASFX completed a strategic acquisition of a European diagnostics firm in early 2025 to expand its molecular testing capabilities; announced a major funding round of $25 million in Q3 2024 led by healthcare-focused venture capital; launched a new line of AI-enhanced imaging systems for point-of-care diagnostics; and formed a key partnership with a leading pharmaceutical distributor to accelerate market penetration in emerging Asian markets. These initiatives reflect ASFX's shift toward integrated digital health solutions and global expansion.